A Phase III, Multicenter, Uncontrolled, Open-label Study to Evaluate Safety and Immunogenicity of a Preservative Free, Inactivated Split Influenza Vaccine, Using the Strain Composition 2009/2010 When Administered to Adult and Elderly Subjects
Latest Information Update: 04 Apr 2022
At a glance
- Drugs Influenza virus vaccine (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Novartis
Most Recent Events
- 30 Jul 2009 New trial record